Friday, 16 October 2026European Markets

NHOA Stock 9.37% Up On Tuesday

Loading stream...

(vianews) - the market ended the session with nhoa (nhoa.pa) jumping 9.37% to €4.20 on tuesday, after five consecutive sessions in a row of losses. cac 40 slid 1.45% to €7,383.20, after two consecutive sessions in a row of gains, on what was an all-around down trend exchanging session today.

nhoa's last close was €3.84, 72.69% under its 52-week high of €14.06.

about nhoa

nhoa s.a. provides energy storage and e-mobility solutions. the company offers solar plus storage, utility-scale storage, and industrial microgrids. it also provides charging services and devices for electric and hybrid vehicles. the company offers energy house, power house, and hybrid house; and hyess, a technology platform for the integration of energy storage system, renewable generation source, as well as conventional generators, as well as atlante, an estation that provides fast charging solution. the company was formerly known as engie eps s.a. and changed its name to nhoa s.a. in july 2021. nhoa s.a. is based in paris, france. nhoa s.a. is a subsidiary of taiwan cement corporation.

earnings per share

as for profitability, nhoa has a trailing twelve months eps of €-1.15.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -58.11%.

more news about nhoa (nhoa.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com